CELLPOINT-DIGITAL
10.11.2021 14:23:03 CET | Business Wire | Press release
CellPoint Digital, a fintech leader in payment orchestration, today announces the next leg of its partnership with Cebu Pacific, the largest airline in the Philippines.
Cebu Pacific is one of the most successful low-cost airlines in the world, having flown over 22 million passengers to over 60 destinations in 2019, with 70% of these bookings being made directly via the carrier’s digital channels.
Following the successful implementation of CellPoint Digital’s cutting-edge Payment Orchestration Platform, Velocity, across all of Cebu Pacific’s digital channels last year, the airline has now implemented new alternative payment methods to provide more flexible options to their customer’s payment experience. Thanks to the PSP/acquirer agnostic Velocity platform, Cebu Pacific customers will now have access to the following popular payment methods: GCash , GrabPay and PayMaya .
The new alternative payment methods boast wide-ranging end-user benefits, including enabling split payments between travel fund vouchers and cash, and converting local currencies in real-time. For the airline itself, providing more payment methods should increase revenues, and by optimising card payment processing across multiple acquirers, they will be able to do real-time transaction monitoring – by market, and by payment method – all delivered conveniently in one place.
The intelligent routing module already dynamically optimises the routing of each transaction made via a bespoke network of acquiring banks, thereby maximising acceptance rates and lowering transaction costs.
Candice Iyog, Vice-president for Marketing and Customer Experience at Cebu Pacific added: “Our partnership with CellPoint Digital continues to go from strength to strength. As the world begins to open back up and consumers are more used to using flexible digital payment methods than ever before, we’re proud to be able to offer our customers a frictionless customer experience at checkout by giving them the payment methods they most want to use.”
Commenting on the announcement Kristian Gjerding, CEO of CellPoint Digital commented: “We’re delighted to announce this evolution in our partnership with Cebu Pacific. Airlines have, by necessity, some of the most complex payment ecosystems of modern merchants, and an equally diverse customer base to match. By utilising our comprehensive payment orchestration platform and having access to a large payments ecosystem, we have simplified the payment process for Cebu while bolstering its offering with popular alternative payment methods for its customers.”
The news comes as the APAC airline sector gears up to take off again following the disruption caused by the COVID-19 pandemic, with 77% of APAC airline customers ready to travel as soon as restrictions fully ease. Via its access to CellPoint Digital’s growing ecosystem, Cebu Pacific is ready to maximise the payments journey for APAC travellers with payment methods covering over 40 local and global cards, and over 350 alternative payment methods.
The future is promising for the partnership as the two companies work towards introducing more new features such as stored cards and other popular APMs, while also empowering Cebu’s B2B offering with more payment capabilities.
To find out more about CellPoint Digital, visit: https://cellpointdigital.com/
To find out more about Cebu Pacific, visit: https://www.cebupacificair.com/
ENDS
About CellPoint Digital
CellPoint Digital makes payments easier™ for airlines, travel companies and other international merchants and their customers.
CellPoint Digital is a fintech leader in payment orchestration. Our main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment eco-system across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rate and minimise payment costs. CellPoint Digital also provides an end-to-end digital commerce platform to airlines that masters the entire customer sales cycle and maximises the conversion rate.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore. Visit www.cellpointdigital.com to learn more.
About Cebu Pacific
Cebu Pacific Air is one of the most successful low-cost carriers in the world and a pioneer of the “low fare, great value” strategy. Cebu started operations in 1996 and has since carried over 150 million passengers. Cebu is the largest carrier in the Philippine air transportation industry, offering low-cost services to more destinations and routes with higher flight frequency within the Philippines than any other airline. It began long-haul services in 2013. Cebu currently offers flights to 37 Philippine and 26 international destinations, spanning Asia, Australia, and the Middle East. Cebu offers a uniquely upbeat flying experience, offering fun in the skies with our “Fun Games” on board. Visit https://cebupacificaircorporate.com/Pages/company-info.aspx to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005810/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom